All In MedTech

Device Trial Radar · NCT06264232

AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

A Multi-center, Prospective, Randomized, Controlled Clinical Trial to Demonstrate the Safety and Effectiveness of the Full Visual Range AT ELANA 841P Posterior Chamber Intraocular Lens for Correction of Aphakia Following Cataract Removal

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 284 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

284

Actual

Start

Jul 12, 2024

Primary completion

Nov 3, 2025

Study completion Dec 1, 2025

Sponsor

Lead sponsor
Carl Zeiss Meditec, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
ORA, Inc.
First posted
Feb 16, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to demonstrate the safety and effectiveness of the full visual range AT ELANA 841P IOL when used to treat adult patients having cataract surgery. Subjects will be randomly selected to receive a pair of IOLs, either the AT ELANA 841P or CT LUCIA 621P lens design. All patients will undergo surgery in both eyes, and they will receive follow up care for up to 6-months. During this time, all patients will undergo thorough eye exams at every study visit and complete questionnaires about their quality of vision post-surgery.

Conditions

  • Cataract Senile

Interventions

  • Cataract SurgeryDevice

    Bilateral removal of age related cataractous lenses with the implantation of intraocular lenses to improve visual acuity.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness OutcomeTime frame: Month 6
  2. Primary Effectiveness OutcomeTime frame: Month 6
  3. Primary Effectiveness OutcomeTime frame: Month 6

5 more outcomes with a free account

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Institute of Ophthalmology

    Beverly Hills, California

  • Mitchell C Shultz MD/Shultz Chang Vision

    Northridge, California

  • Coastal Vision Medical Group

    Orange, California

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.